An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Trial Status: active
This is a randomized, open-label study in adult patients who have completed standard
first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or
partial response suitable for observation, but who have minimal residual disease (MRD) as
detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by
PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of
consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T
product, as compared to standard of care observation.
In this study, participants with MRD are randomized 1:1 to treatment with cema-cel or an
observation arm. Treatment includes cema-cel following a lymphodepletion regimen of
fludarabine and cyclophosphamide.
Prior to August 2025, participants may also have received an anti-CD52 monoclonal
antibody, ALLO-647, as part of their lymphodepletion regimen.
Inclusion Criteria
LBCL per WHO 2017 including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, and primary mediastinal B-cell lymphoma histologically confirmed by pathology report.
Participant has completed a full course of standard first line therapy (e.g., R-CHOP, dose-adjusted EPOCH-R, Pola-R-CHP) as intended. Participants cannot have received additional lines of therapy.
Participant achieved CR, or PR suitable for observation, at the end of first line therapy based on PET/CT evaluation
Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™, is positive.
Adult participants ≥18 years of age.
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
Adequate hematological, renal, hepatic, pulmonary, and cardiac function
Non-hematologic toxicities related to prior therapy must be recovered to baseline or grade ≤1. Key
Exclusion Criteria
LBCL with history of central nervous system involvement, transformed from other malignancy (e.g., transformed follicular lymphoma or marginal zone lymphoma, Richter's transformation), or T-cell/histiocyte rich LBCL.
Prior treatment with anti-CD19 targeted therapies.
Anti-cancer treatment, including radiation, after end of treatment PET/CT and/or MRD testing is performed.
Active and clinically significant autoimmune disease.
Active systemic bacterial, fungal, or viral infections requiring systemic treatment.
History of another primary malignancy or bone marrow disorder (e.g., myelofibrosis, smoldering multiple myeloma) within 3 years prior to enrollment.
Additional locations may be listed on ClinicalTrials.gov for NCT06500273.
